Blue , its good to have a differing view, but for someone who doesn't own the stock arent you going out of your way to make a point. Enough said, give it a rest its getting stale mate.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
